Results 101 to 110 of about 6,506,258 (188)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

open access: yes, 2015
Nishanth Vallumsetla, Jonas Paludo, Prashant Kapoor Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA Abstract: Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma ...
Paludo J, Kapoor P, Vallumsetla N
core  

Ibrutinib plus Venetoclax May Be Effective in Mantle-Cell Lymphoma

open access: yes, 2018
Ibrutinib plus venetoclax is superior to monotherapy in patients with mantle-cell lymphoma.

core   +1 more source

[Cytogenetics of mantle cell lymphoma].

open access: yesTerapevticheskii arkhiv, 2004
To determine the type and rate of secondary chromosomal aberrations and role in pathogenesis of mantle cell lymphoma (MCL).Standard cytogenetic examination (SCE) and fluorescent in situ hybridization (FISH) with tests for 11q22/ATM, 13q14, 17p13/p53, 9p21/p16 and chromosome 12 centromere were made in 28 patients.Secondary chromosomal aberrations were ...
T N Obukhova   +7 more
openaire   +2 more sources

Endotracheal Involvement as an Unusual Extranodal Site of Recurrence from Mantle

open access: yes, 2014
Mantle cell lymphomas are uncommon subtypes of non-Hodgkin’s lymphoma with poor overall survival ranging from 3-5 years. Patients are often middle aged men who would present with generalized lymphadenopathy and typical constitutional symptoms. Extranodal
Ann Mcgeehan   +2 more
core  

Case Report: Occult mantle cell lymphoma in a synchronous rectal collision tumor with adenocarcinoma: retrospective reclassification and multispecimen molecular profiling

open access: yesFrontiers in Oncology
Collision tumors composed of colorectal adenocarcinoma and mantle cell lymphoma are exceptionally rare, and component-resolved molecular characterization is largely lacking. We report a 65-year-old woman who initially presented with rectal adenocarcinoma
Qing Zhang   +3 more
doaj   +1 more source

Pulmonary mantle cell lymphoma: a rare manifestation of an uncommon condition

open access: yesRare Tumors, 2012
Herein we describe the case of a 64-year old man with a history of mantle cell lymphoma found to have evidence of pulmonary parenchymal involvement by recurrence of his lymphoma.
Zachary S. DePew, Robert Vassallo
doaj   +1 more source

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair   +11 more
wiley   +1 more source

Molecular Pathogenesis of MALT lymphoma [PDF]

open access: yes, 2011
Mucosa associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway.

core   +2 more sources

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non‐Hodgkin Lymphoma on Reproduction Patterns

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1601-1611, December 2026.
ABSTRACT Concerns about treatment‐related fertility impairment are common among young adult lymphoma survivors. Evidence on the impact of treatment for aggressive non‐Hodgkin lymphoma (NHL) on future childbearing is limited, although many individuals of reproductive age are affected.
Stefanie Antonilli   +10 more
wiley   +1 more source

The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis

open access: yesChemMedChem, Volume 21, Issue 21, 12 November 2026.
Can a single element help address the multifactorial nature of ALS? Boron‐containing compounds combine responsiveness to reactive oxygen species (ROS), neuroprotective activity, and favorable pharmacological properties, offering a distinctive framework for disease modification in a complex disease like ALS.
Nitesh Sanghai   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy